Responses

PDF

Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests

PLEASE NOTE:

  • Responses are moderated before posting and publication is at the absolute discretion of BMJ, however they are not peer-reviewed
  • Once published, you will not have the right to remove or edit your response. Removal or editing of responses is at BMJ's absolute discretion
  • If patients could recognise themselves, or anyone else could recognise a patient from your description, please obtain the patient's written consent to publication and send them to the editorial office before submitting your response [Patient consent forms]
  • By submitting this response you are agreeing to our full [Response terms and requirements]

Vertical Tabs

Other responses

  • Published on:
    Re: Identification of Pneumocystis colonization in patients treated with Infliximab

    Dear Editor,

    We thank Dr Wissmann for the eLetter concerning Pneumocystis jiroveci pneumonia (PCP) to our article, "Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis 2008;67:189-194.

    We reported that PCP developed in 22 patients among 5,000 patients with RA treated with infliximab. The organism of Pneumocysits jiroveci was not i...

    Show More
    Conflict of Interest:
    None declared.
  • Published on:
    Identification of Pneumocystis colonization in patients treated with Infliximab
    • Gustavo Wissmann, Postdoctoral fellow
    • Other Contributors:
      • Isabel M Garrido, Nieves Respaldiza, Jose M. Varela, and Enrique Calderón

    Dear Editor,

    The introduction of biological agents resulted in a paradigm shift in the treatment of rheumatoid arthritis (RA). Infliximab, a chimeric anti-tumor necrosis factor (TNF)-α monoclonal antibody, has become an established effective therapy for RA. However, despite its role in chronic inflammatory diseases, evidence shows that TNF-α is also a critical factor in host defense. TNF-α initiates the inflammator...

    Show More
    Conflict of Interest:
    None declared.